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Abstract
Aims/hypothesis The aim of this study was to investigate
the association of the rs10811661 polymorphism near the
CDKN2B/CDKN2A genes with glucose tolerance, insulin
sensitivity and insulin release in three samples of white
people with European ancestry.
Methods Sample 1 comprised 845 non-diabetic offspring of
type 2 diabetes patients recruited in five European centres
participating in the EUGENE2 study. Samples 2 and 3
comprised, respectively, 864 and 524 Italian non-diabetic
participants. All individuals underwent an OGTT. Screen-
ing for the rs10811661 polymorphism was performed using
a TaqMan allelic discrimination assay.
Results The rs10811661 polymorphism did not show a
significant association with age, BMI and insulin sensitiv-
ity. Participants carrying the TT genotype showed a
significant reduction in insulin release, measured by an
OGTT-derived index, compared with carriers of the
C allele, in the three samples. When these results were
pooled with those of three published studies, and meta-
analysed with a random-effects model, the T allele was
significantly associated with reduced insulin secretion
(−35.09 [95% CI 14.68–55.52], p=0.0008 for CC+CT vs
TT; and −29.45 [95% CI 9.51–49.38], p=0.0038, for the
additive model). In addition, in our three samples, partic-
ipants carrying the TT genotype exhibited an increased risk
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for impaired glucose tolerance (IGT) compared with
carriers of the C allele (OR 1.55 [95% CI 1.20–1.95] for
the meta-analysis of the three samples).
Conclusions/interpretation Our data, together with the
meta-analysis of previously published studies, show that
the rs10811661 polymorphism is associated with impaired
insulin release and IGT, suggesting that this variant may
contribute to type 2 diabetes by affecting beta cell function.
Keywords Beta cell dysfunction .CDKN2A/CDKN2B .
Genetics . Insulin .Meta-analysis . Offspring . Type 2
diabetes
Abbreviations
CATAMERIS CAtanzaro MEtabolic RIsk factors Study
CDK4 Cyclin-dependent kinase 4
CDK6 Cyclin-dependent kinase 6
DPP Diabetes Prevention Program
GWA Genome-wide association
IGT Impaired glucose tolerance
ISI Matsuda index of insulin sensitivity
p15INK4a Cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
p15INK4b Cyclin-dependent kinase inhibitor 2B
(p15, inhibits CDK4)
Introduction
The pathophysiology of type 2 diabetes is characterised by
a combination of impaired insulin action at the level of
skeletal muscle, fat and liver, and failure of pancreatic beta
cells to compensate for the enhanced insulin demand,
ultimately resulting in hyperglycaemia [1, 2]. The patho-
genesis of these two components is generally thought to be
multifactorial, involving both genetic susceptibility and
environmental factors [3]. However, identifying genes that
confer susceptibility to type 2 diabetes has proven
problematic. The availability of high-density genotyping
arrays has enabled a systematic search for type 2 diabetes-
associated common variants on a genome-wide scale [4–9].
Results of these studies have led to the identification of
novel risk loci for type 2 diabetes. Among these loci, a
polymorphism on chromosome 9p (rs10811661), located
125 kb upstream of the CDKN2B and CDKN2A genes
(encoding cyclin-dependent kinase inhibitor 2B (p15,
inhibits CDK4) [p15INK4b] and cyclin-dependent kinase
inhibitor 2A (melanoma, p16, inhibits CDK4) [p16INK4a],
respectively), has been associated with type 2 diabetes in
three of the genome-wide association (GWA) studies (OR
for pooled studies 1.20 [95% CI 1.14–1.25], p=5×10−15)
[6–8]. This association was replicated in several popula-
tions including Danish, Norwegian, French, Korean, Japa-
nese and Chinese participants [10–15], but not confirmed in
African-Americans and Pima Indians [16, 17]. Furthermore,
the polymorphism rs10811661 was not associated with
incident diabetes in the Diabetes Prevention Program (DPP)
[18].
p15INK4b and p16INK4a, the proteins encoded by the
CDKN2B and CDKN2A genes, are tumour suppressors that
inhibit cyclin-dependent kinase 6 (CDK6) and CDK4,
respectively, two regulators of pancreatic beta cell replica-
tion [19–21]. Both CDKN2B and CDKN2A are expressed in
pancreatic islets and adipocytes [6–8]. In murine models, it
has been demonstrated that increased production of
p15INK4b is associated with pancreatic islet hypoplasia and
impaired glucose-induced insulin secretion [19]. On the
other hand, mice lacking CDK4 exhibit insulin-deficient
diabetes due to a reduction in pancreatic beta cells, and
mice expressing a mutant CDK4 that cannot bind the cell-
cycle inhibitor p16INK4a display pancreatic hyperplasia due
to proliferation of beta cells [20, 21]. These data suggest
that the rs10811661 polymorphism located upstream of the
CDKN2B and CDKN2A genes may confer increased risk
for type 2 diabetes by affecting beta cell function. However,
studies aimed at evaluating the potential role of the
rs10811661 polymorphism in affecting quantitative meta-
bolic traits associated with the risk of diabetes, such as
measures of beta cell function and insulin sensitivity, have
led to discordant results. Two studies have reported that
non-diabetic carriers of the type 2 diabetes risk allele (T),
the rs10811661 polymorphism, had lower insulin release
during an OGTT [10, 22], whereas other studies carried out
in participants of European ancestry and in Pima Indians
did not find an association between this polymorphism and
insulin secretion [17, 23, 24]. Thus, in order to obtain
additional data on the association of the rs10811661
polymorphism with impaired glucose tolerance and patho-
physiological quantitative traits, i.e. measures of beta cell
function and insulin sensitivity, we studied three well-
characterised samples of white Europeans.
Methods
Three different samples of adult (≥18 years of age) non-
diabetic white people of European ancestry were studied.
Sample 1 comprised 845 non-diabetic offspring who had
one parent with type 2 diabetes and the other parent with no
family history of type 2 diabetes and/or a normal response to
an OGTT. The offspring of type 2 diabetic patients were
recruited in five different European centres participating in the
EUGENE2 project (www.eugene2.com) [25] as follows:
Copenhagen, Denmark (n=268), Kuopio, Finland (n=217),
Tübingen, Germany (n=152), Catanzaro, Italy (n=109) and
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Gothenburg, Sweden (n=99). Of these, 136 individuals
(16.1%) had impaired glucose tolerance (IGT).
All study centres followed the same protocol, as
previously reported [25]. Briefly, all participants underwent
anthropometrical evaluation, and a 75 g OGTT was
performed with 0, 30, 60, 90 and 120 min sampling for
plasma glucose and insulin. On the second visit after a 12 h
fast, the participants underwent a euglycaemic hyperinsu-
linaemic clamp study. The rate of total insulin-stimulated
glucose disposal (M) was calculated for the last 60 min of
the insulin infusion. In the Copenhagen centre, the
euglycaemic clamp was not performed. Glucose levels
were measured by the glucose oxidase method. Because
plasma insulin was measured by different methods (except
for the Gothenburg centre, for which insulin was measured
in Tübingen), the assay applied in Tübingen (micro-particle
enzyme immunoassay; Abbott Laboratories, Tokyo, Japan)
was selected as a reference assay. The Catanzaro, Copen-
hagen and Kuopio centres each sent between 40 and 100
fasting and post-glucose challenge plasma insulin samples
for parallel analysis in Tübingen. Plasma insulin levels
from these three centres were converted by linear regression
analysis to plasma insulin levels corresponding to the
Tübingen assay.
Sample 2 comprised 864 unrelated non-diabetic individ-
uals participating in the CAtanzaro MEtabolic RIsk factors
Study (CATAMERIS), an observational study focused on
assessment of cardio-metabolic risk factors [26]. Of these,
237 individuals (27.5%) had IGT.
Sample 3 comprised 524 unrelated non-diabetic partic-
ipants consecutively recruited at the Department of Internal
Medicine of the University of Rome-Tor Vergata [27]. Of
these, 125 individuals (23.9%) had IGT. All participants
included in samples 2 and 3 underwent anthropometrical
evaluation and a venous blood sample was drawn for
laboratory determination. After a 12 h overnight fast, a 75 g
OGTT was performed with 0, 30, 60 and 120 min sampling
for plasma glucose and insulin. The Matsuda index of
insulin sensitivity (ISI) was calculated as described by
Matsuda and DeFronzo [28]. Glucose-stimulated insulin
secretion was estimated using the Stumvoll index for first-
phase insulin secretion and was calculated as: 2,503+6.476 ×
insulin0 (pmol/l) − 126.5 × glucose120 (mmol/l) + 0.954 ×
insulin120 (pmol/l) − 239.3 × glucose0 (mmol/l), as
previously described [29].
The study protocol was approved by appropriate
institutional review boards and was in accordance with the
Helsinki Declaration II. All study participants gave
informed consent.
DNA analysis DNA was isolated from whole blood using
commercial DNA isolation kits. Samples from the
EUGENE2 Consortium were genotyped in the Kuopio
centre, whereas the two Italian samples were genotyped in
the Catanzaro centre. Screening of the rs10811661 poly-
morphism was performed using a TaqMan allelic discrim-
ination assay (Applied Biosystems, Foster City, CA, USA).
The TaqMan genotyping reaction was amplified on a
GeneAmp PCR system 2700 (Applied Biosystems) and
fluorescence was detected using an ABI Prism 7000
sequence detector (Applied Biosystems). The overall
genotyping success rate was 99.5%; genotype distributions
obeyed Hardy–Weinberg equilibrium in the three different
samples.
Statistical analysis Data analyses were performed using
Statistical Package for Social Science (SPSS Inc., Chicago,
IL, USA) version 14.0. The results for continuous variables
are given as means ± SD. Because of the low number of CC
homozygotes in the study samples, the rs10811661 poly-
morphism was tested using both the additive and the
dominant inheritance model. Unpaired Student’s t tests or
ANOVAs were used to compare differences among groups
for continuous variables, as appropriate, and the χ2 test for
non-continuous variables. A general linear model was used
to compare phenotypic differences in the three samples. A
multivariable logistic regression analysis, adjusted for age,
sex and centre, was used to determine the association
between the genotype frequencies and IGT. We report a
nominal p value of <0.05 without adjustment for multiple
testing given the high prior probabilities for association of
the rs10811661 polymorphism with the examined pheno-
types. A fixed-effect meta-analysis was performed using a
comprehensive meta-analysis programme to assess the
global OR for IGT in samples 1–3. To meta-analyse the
effect of rs10811661 on insulin secretion in the three
samples analysed in this study, together with three
previously published studies [10, 22, 23], effect size
estimates and standard errors from the six samples were
pooled by RGui version 2.10.0 (www.r-project.org) apply-
ing the meta package and the combined effect was derived
from the random-effects method (weight of studies estimat-
ed using the DerSimonian–Laird method [30]).
Results
The clinical characteristics of sample 1 according to the
rs10811661 polymorphism are shown in Table 1. The
rs10811661 polymorphism did not show any significant
association with age, BMI or fasting plasma glucose levels.
We also found no association between the rs10811661
polymorphism and whole-body insulin sensitivity as mea-
sured by a hyperinsulinaemic, euglycaemic clamp
(M value; Table 1). By contrast, the rs10811661 polymor-
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phism was significantly associated with 2 h post-load
glucose levels, with carriers of the C allele having
significantly lower levels compared with participants
carrying the TT genotype (p=0.03 according to a dominant
model; Table 1). In addition, the rs10811661 polymorphism
was significantly associated with the OGTT-derived index
of insulin secretion, with participants carrying the TT
genotype showing a significant reduction in insulin release
compared with carriers of the C allele (p=0.03). In a
logistic regression analysis with adjustment for age, sex and
centre, participants carrying the TT genotype exhibited an
increased risk for IGT compared with carriers of the C
allele (OR 1.78 [95% CI 1.12–2.82], p=0.014).
To replicate these data, two independent samples of non-
diabetic Italian individuals were studied. The clinical
characteristics of sample 2 according to the rs10811661
polymorphism are shown in Table 2. The rs10811661
polymorphism did not show any significant association
with age, BMI, fasting plasma glucose levels or insulin
sensitivity as measured by the ISI index. Carriers of the
C allele have significantly lower levels of 2 h post-load
glucose levels compared with participants carrying the TT
genotype (p=0.04 according to a dominant model; Table 2).
Furthermore, the rs10811661 polymorphism was signifi-
cantly associated with the OGTT-derived index of insulin
secretion, with participants carrying the TT genotype
showing a significant reduction in insulin release compared
with carriers of the C allele (p=0.05). In a logistic
regression analysis with adjustment for age and sex,
participants carrying the TT genotype exhibited an in-
creased risk for IGT, compared with carriers of the C allele
(OR 1.44 [95% CI 1.02–2.03], p=0.04).
Clinical characteristics of sample 3 according to the
rs10811661 polymorphism are shown in Table 3. The
rs10811661 polymorphism was not associated with age,
BMI or insulin sensitivity as measured by the ISI index.
Carriers of the C allele showed significantly lower fasting
and 2 h post-load glucose levels compared with participants
carrying the TT genotype (p=0.01 and p=0.04 according to
the dominant model, for fasting and 2 h post-load glucose,
respectively). In addition, the rs10811661 polymorphism
was significantly associated with the OGTT-derived index
of insulin secretion, with participants carrying the TT
genotype showing a significant reduction in insulin release
compared with carriers of the C allele (p=0.03). In a
logistic regression analysis with adjustment for age and sex,
participants carrying the TT genotype exhibited an in-
creased risk for IGT compared with carriers of the C allele
(OR 1.61 [95% CI 1.01–2.59], p=0.04).
As no genetic heterogeneity across the three samples was
evident (p value for heterogeneity=0.76), data from the
three samples were meta-analysed with a fixed-effect
model. The results of this meta-analysis showed that
participants carrying the TT genotype have an OR for
Table 1 Clinical and metabolic characteristics of 845 non-diabetic offspring of patients with type 2 diabetes according to the rs10811661
polymorphism at CDKN2A/B
Variable rs10811661 genotype p value p valuea
TT TC CC TT vs TC vs CC TT vs TC+CC
Men/women (n=845) 261/345 83/140 7/9 0.31 0.15
Age (years) 40±10 40±10 40±9 0.90b 0.99b
BMI (kg/m2) 26.6±5.0 26.9±4.9 25.9±5.2 0.64c 0.92c
Fasting glucose (mmol/l) 5.05±0.55 5.1±0.5 4.77±0.5 0.11 0.46
2 h post-load glucose (mmol/l) 6.38±1.6 6.05±1.5 6.22±1.6 0.03 0.03
Stumvoll first-phase insulin
secretion index
1,114±412 1,200±628 1,212±340 0.05 0.03
Glucose disposal
(μmol kg–1 min–1) (n=577)
41.5±16.3 (n=413) 41.7±17.2 (n=150) 37.6±16.6 (n=14) 0.15 0.20
Disposition index (Stumvoll
first-phase insulin secretion
index × glucose disposal) (n=577)
45,335±19,301 48,526±26,391 45,768±20,170 0.31 0.14
NGT/IGT, n/n (%) 497/109 (18) 199/24 (10.8) 13/3 (18.8) 0.04 0.01
Data are mean ± SD
Comparisons between the three groups were performed using a general linear model. Categorical variables were compared by χ2 test. p values are
after adjustment for centre, age, sex and BMI
NGT, normal glucose tolerance
a p values for comparisons of differences in continuous variables in a dominant model while adjusting for age, sex and BMI
b p values after adjustment for centre and sex
c p values after adjustment for centre, age and sex
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IGT of 1.55 (95% CI 1.20–1.95, p=0.0001) compared with
carriers of the C allele.
Finally, in order to provide a more confident estimate of
the effect of rs10811661 on insulin secretion, the results for
the three samples analysed in this study were pooled with
those of three available studies on European non-diabetic
participants [10, 22, 23]. Borderline significant heterogene-
ity indicating differential effects between the studies was
observed in the meta-analysis (p=0.068 for the dominant
model and p=0.053 for the additive model). When data for
Table 2 Clinical and metabolic characteristics of 864 non-diabetic unrelated participants according to the rs10811661 polymorphism at
CDKN2A/B
Variable rs10811661 genotype p value p valuea
TT TC CC TT vs TC vs CC TT vs TC+CC
Men/women 301/281 121/121 27/13 0.11 0.33
Age (years) 50±13 50±12 50±13 0.92b 0.70b
BMI (kg/m2) 30.3±5.6 30.0±5.4 30.9±6.1 0.37c 0.46c
Fasting glucose (mmol/l) 5.27±0.66 5.22±0.61 5.27±0.61 0.25 0.10
2 h post-load glucose (mmol/l) 6.94±2.33 6.78±1.94 5.89±1.27 0.003 0.04
Stumvoll first-phase insulin secretion index 1,325±520 1,389±621 1,576±569 0.03 0.03
Matsuda index/ISI 69±42 75±41 60±34 0.52 0.12
Disposition index (Stumvoll first-phase index
insulin secretion × Matsuda index)
84,716±47,196 89,437±40,994 80,371±30,548 0.24 0.11
NGT/IGT, n/n (%) 409/172 (29.6) 183/59 (24.4) 35/5 (12.5) 0.03 0.03
Data are mean ± SD
Comparisons between the three groups were performed using a general linear model. Categorical variables were compared by χ2 test. p values are
after adjustment for age, sex and BMI
NGT, normal glucose tolerance
a p values for comparisons of differences in continuous variables in a dominant model while adjusting for age, sex and BMI
b p values after adjustment for sex
c p values after adjustment for age and sex
Table 3 Clinical and metabolic characteristics of 524 non-diabetic unrelated participants according to the rs10811661 polymorphism at
CDKN2A/B
Variable rs10811661 genotype p value p valuea
TT TC CC TT vs TC vs CC TT vs TC+CC
Men/women 122/232 47/96 9/18 0.94 0.73
Age (years) 42±13 42±13 38±11 0.28b 0.66b
BMI (kg/m2) 30.0±7.2 29.9±7.8 27.5±6.7 0.27c 0.46c
Fasting glucose (mmol/l) 5.05±0.67 4.89±0.55 4.78±0.55 0.07 0.01
2 h post-load glucose (mmol/l) 6.61±1.94 6.33±1.83 5.67±1.78 0.02 0.04
Stumvoll first-phase insulin secretion index 1,302±513 1,430±677 1,471±697 0.02 0.007
Matsuda index/ISI 88±52 89±55 99±60 0.52 0.57
Disposition index (Stumvoll first-phase
insulin secretion index × Matsuda index)
104,173±56,150 110,106±58,113 123,465±55,368 0.34 0.15
NGT/IGT (%) 260/94 (26.6) 115/28 (19.6) 24/3 (11.1) 0.07 0.03
Data are mean ± SD
Comparisons between the three groups were performed using a general linear model. Categorical variables were compared by χ2 test. p values are
after adjustment for age, sex and BMI.
NGT, normal glucose tolerance
a p values for comparisons of differences in continuous variables in a dominant model while adjusting for age, sex and BMI
b p values after adjustment for sex
c p values after adjustment for age and sex
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the 13,896 individuals were meta-analysed with a random-
effects model, the T allele was significantly associated with
reduced insulin secretion (−35.09 [95% CI 14.68–55.52], p=
0.0008 for CC+CT vs TT; and −29.45 [95% CI 9.51–49.38],
p=0.0038, for the additive model; Fig. 1).
Discussion
The present study aimed to elucidate the metabolic effects
of the rs10811661 polymorphism, which has been recently
identified as a type 2 diabetes susceptibility locus by GWA
studies [6–8]. Using three samples of non-diabetic white
people of European ancestry, we found that the rs10811661
polymorphism of CDKN2B/CDKN2A was significantly
associated with impaired glucose-stimulated insulin release,
but not with insulin sensitivity as measured by hyper-
insulinaemic, euglycaemic clamp (sample 1) or by an
OGTT-derived index of insulin sensitivity (samples 2 and
3). Association of the rs10811661 polymorphism of
CDKN2B/CDKN2A with estimates of insulin release de-
rived from an OGTT has been evaluated in previous
studies, with divergent results [10, 17, 22–24]. In the
Danish population-based Inter99 study, comprising 5,970
middle-aged participants, it was reported that carriers of the
C allele had an estimated higher level of insulin release in
response to an oral glucose load compared with participants
carrying the TT genotype [10]; similar results were
observed in a study of 5,327 non-diabetic Finnish men
[22]. Interestingly, when we performed a meta-analysis
including our samples and data from three previously
published studies [10, 22, 23], we observed that the
T allele was significantly associated with reduced insulin
secretion. Of note, in Pima Indians, the rs10811661
polymorphism was not associated with either type 2
diabetes or insulin release [17]. The reasons for these
discrepancies are unclear. Difference in ethnicity is the most
obvious explanation for these divergent results. In support
of this hypothesis, several type 2 diabetes risk variants
found in Europid participants, such as polymorphisms in
CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2 and
LOC387761, were not significantly associated with type 2
diabetes in Pima Indians [17]; furthermore it is possible that
the lack of data on the causative variant associated with the
variant under study may play a role in the discrepancies
between the different ethnicities.
We also found that participants carrying the TT genotype
have higher 2 h post-load glucose levels and increased risk of
IGT (OR 1.55 [95%CI 1.20–1.95] in the pooled data from the
three samples) compared with carriers of the C allele.
Interestingly, participants carrying the low-risk CC genotype
at the CDKN2A/B locus enrolled in the DPP exhibited a
greater improvement in beta cell function than those with the
high-risk TT genotype after treatment with troglitazone and
lifestyle modification for 1 year, suggesting that they may
have benefited more from these interventions [18].
Mechanisms underlying the association of the
rs10811661 polymorphism with impaired insulin secretion
and the risk of IGT and type 2 diabetes are not fully
understood. The nearest annotated genes CDKN2B and
CDKN2A, encoding p15INK4b and p16INK4a, respectively,
have been implicated in pancreatic islet regenerative
capacity [19, 31]. p16INK4a has been shown to accumulate
in many tissues, including pancreatic islets, as a function of
ageing [32, 33]. Transgenic mice overproducing p16INK4a
showed decreased islet proliferation with ageing, and aged
mice lacking p16INK4a demonstrated enhanced islet prolif-
eration. These observations support the idea that p16INK4a
mediates a decline in the replicative capacity of beta cells
associated with ageing. Because type 2 diabetes mellitus
patients exhibit a decrease in beta cell mass [34], it may be
tempting to speculate that increased p16INK4a levels with
ageing may contribute to the relative failure of islet
proliferation associated with type 2 diabetes mellitus.
However, a recent study, evaluating whether genetic
variants robustly associated with type 2 diabetes also
modulate expression levels of nearby candidate genes, has
Fig. 1 Results of the meta-analysis of the association of the
rs10811661polymorphism at CDKN2A/B and insulin secretion in
13,986 individuals. a CC+CT vs TT: −35.09 (95% CI 14.68–55.52),
p=0.0008 (diamond) and (b) additive model: −29.45 (95% CI 9.51–
49.38), p=0.0038 (diamond)
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reported no evidence of an association between the
rs10811661 polymorphism and CDKN2B and CDKN2A
gene expression in human tissues [35].
This study has some limitations. The present findings
obtained in a cross-sectional study of cohorts of Europids
are explorative in nature and replication in independent
prospective population-based studies with different ethnic-
ities is needed to firmly determine whether the rs10811661
polymorphism affects insulin secretion and whether pan-
creatic beta cell dysfunction is truly implicated in the
pathogenesis of type 2 diabetes.
Acknowledgements This study was supported by a grant from the
European Community’s FP6 EUGENE2 no. LSHM-CT-2004-512013.
The EUGENE2 Consortium (www.eugene2.com) consists of the
laboratories of: U. Smith (Sweden), M. Laakso (Finland), H. Haring
(Germany), G. Sesti (Italy), O. Pedersen (Denmark), J. Zierath
(Sweden), H.-G. Joost (Germany), F. Beguinot (Italy), E. van
Obberghen (France), J. Auwerx (France), F. Bosch (Spain), P. Lind
(Sweden).
Duality of interest N. Grarup, T. Hansen and O. Pedersen hold
personal shares in Novo Nordisk. M. L. Hribal, I. Presta, T. Procopio,
M. A. Marini, A. Stančáková, J. Kuusisto, F. Andreozzi,
A. Hammarstedt, P-A Jansson, M. Walker, N. Stefan, A. Fritsche,
H. U. Häring, U. Smith, M. Laakso and G. Sesti declare that they have
no conflict of interest associated with this manuscript.
References
1. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR
(1990) Slow glucose removal rate and hyperinsulinemia precede
the development of type II diabetes in the offspring of diabetic
parents. Ann Intern Med 113:909–915
2. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M,
Laakso M (1998) Defects in insulin secretion and insulin action in
non-insulin-dependent diabetes mellitus are inherited: metabolic
studies on offspring of diabetic probands. J Clin Invest 101:86–
96
3. Permutt MA, Wasson J, Cox N (2005) Genetic epidemiology of
diabetes. J Clin Invest 115:1431–1439
4. Frayling TM, Timpson NJ, Weedon MN et al (2007) A common
variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science 316:889–894
5. Steinthorsdottir V, Thorleifsson G, Reynisdottir I et al (2007) A
variant in CDKAL1 influences insulin response and risk of type 2
diabetes. Nat Genet 39:770–775
6. Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of
genome-wide association signals in U.K. samples reveals risk loci
for type 2 diabetes. Science 316:1336–1341
7. Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide
association analysis identifies loci for type 2 diabetes and
triglyceride levels. Science 316:1341–1345
8. Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) Genome-wide
association study of type 2 diabetes in Finns detects multiple
susceptibility variants. Science 316:1341–1345
9. Wellcome TCCC (2007) Genome-wide association study of
14,000 cases of seven common diseases and 3,000 shared
controls. Nature 447:661–678
10. Grarup N, Rose CS, Andersson EA et al (2007) Studies of
association of variants near the HHEX, CDKN2A/B, and
IGF2BP2 genes with type 2 diabetes and impaired insulin release
in 10,705 Danish subjects: validation and extension of genome-
wide association studies. Diabetes 56:3105–3111
11. Hertel JK, Johansson S, Raeder H et al (2008) Genetic analysis of
recently identified type 2 diabetes loci in 1,638 unselected patients
with type 2 diabetes and 1,858 control participants from a
Norwegian population-based cohort (the HUNT Study). Diabeto-
logia 51:971–977
12. Duesing K, Fatemifar G, Charpentier G et al (2008) Strong
association of common variants in the CDKN2A/CDKN2B region
with type 2 diabetes in French Europids. Diabetologia 51:821–
826
13. Lee YH, Kang ES, Kim SH et al (2008) Association between
polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2,
FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the
Korean population. J Hum Genet 53:991–998
14. Wu Y, Li H, Loos RJ et al (2008) Common variants in CDKAL1,
CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are
associated with type 2 diabetes and impaired fasting glucose in a
Chinese Han population. Diabetes 57:2834–2842
15. Tabara Y, Osawa H, Kawamoto R et al (2009) Replication study
of candidate genes associated with type 2 diabetes based on
genome-wide screening. Diabetes 58:493–498
16. Lewis JP, Palmer ND, Hicks PJ et al (2008) Association analysis
in African Americans of European-derived type 2 diabetes single
nucleotide polymorphisms from whole-genome association stud-
ies. Diabetes 57:2220–2225
17. Rong R, Hanson RL, Ortiz D et al (2009) Association analysis of
variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2,
IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and
related quantitative traits in Pima Indians. Diabetes 58:478–488
18. Moore AF, Jablonski KA, McAteer JB et al (2008) Diabetes
Prevention Program Research Group. Extension of type 2 diabetes
genome-wide association scan results in the diabetes prevention
program. Diabetes 57:2503–2510
19. Moritani M, Yamasaki S, Kagami M et al (2005) Hypoplasia of
endocrine and exocrine pancreas in homozygous transgenic TGF-
beta1. Mol Cell Endocrinol 229:175–184
20. Rane SG, Dubus P, Mettus RV et al (1999) Loss of Cdk4
expression causes insulin-deficient diabetes and Cdk4 activation
results in beta-islet cell hyperplasia. Nat Genet 22:44–52
21. Tsutsui T, Hesabi B, Moons DS et al (1999) Targeted disruption of
CDK4 delays cell cycle entry with enhanced p27 (Kip1) activity.
Mol Cell Biol 19:7011–7019
22. Stancáková A, Kuulasmaa T, Paananen J et al (2009) Association
of 18 confirmed susceptibility loci for type 2 diabetes with indices
of insulin release, proinsulin conversion, and insulin sensitivity in
5,327 nondiabetic Finnish men. Diabetes 58:2129–2136
23. Pascoe L, Tura A, Patel SK et al (2007) Common variants of the
novel type 2 diabetes genes CDKAL1 and HHEX/IDE are
associated with decreased pancreatic beta-cell function. Diabetes
56:3101–3104
24. Groenewoud MJ, Dekker JM, Fritsche A et al (2008) Variants of
CDKAL1 and IGF2BP2 affect first-phase insulin secretion during
hyperglycaemic clamps. Diabetologia 51:1659–1663
25. Laakso M, Zilinskaite J, Hansen T et al (2008) Insulin sensitivity,
insulin release and GLP-1 levels in subjects with IFG and/or IGT
in the EUGENE2 Study. Diabetologia 51:502–511
26. Succurro E, Marini MA, Arturi F et al (2009) Elevated one-hour
post-load plasma glucose levels identifies subjects with normal
glucose tolerance but early carotid atherosclerosis. Atherosclerosis
207:245–249
27. Sesti G, Cardellini M, Marini MA et al (2003) A common
polymorphism in the promoter of UCP2 contributes to the
variation in insulin secretion in glucose-tolerant subjects. Diabetes
52:1280–1283
Diabetologia (2011) 54:795–802 801
28. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices
obtained from oral glucose tolerance testing: comparison with the
euglycemic insulin clamp. Diab Care 9:1462–1470
29. Stumvoll M, van Haeften T, Fritsche A, Gerich J (2001) Oral
glucose tolerance test indexes for insulin sensitivity and secretion
based on various availabilities of sampling times. Diab Care
24:796–797
30. Der Simonian R, Laird N (1986) Meta-analysis in clinical trials.
Control Clin Trials 7:177–188
31. Krishnamurthy J, Ramsey MR, Ligon KL et al (2006) p16INK4a
induces an age-dependent decline in islet regenerative potential.
Nature 443:453–457
32. Krishnamurthy J, Torrice C, Ramsey MR et al (2004) Ink4a/Arf
expression is a biomarker of aging. J Clin Invest 114:1299–1307
33. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J,
Louis DN (1999) Immunohistochemical survey of p16INK4A
expression in normal human adult and infant tissues. Lab Invest
79:1137–1143
34. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA,
Butler PC (2003) Beta-cell deficit and increased beta-cell
apoptosis in humans with type 2 diabetes. Diabetes 52:102–110
35. Cotsapas C, Prokunina-Olsson L, Welch C et al (2010) Expression
analysis of loci associated with type 2 diabetes in human tissues.
Diabetologia 53:2334–2339
802 Diabetologia (2011) 54:795–802
